Facebook
Twitter
LinkedIn
Forward
Examining and Addressing Disparities in Multiple Myeloma Treatment & Outcomes
- This evenings in oncology program will be a virtual (online) event. -
Overview:
Multiple myeloma (MM) is a currently incurable malignancy that is primarily characterized by immunodeficiency, malignant plasma cell proliferation, and osteolytic bone lesions. MM is the 2nd second most common hematologic malignancy worldwide, with approximately ~35,000 new cases and more than 12,000 deaths annually in the United States, Despite advancements in first-line therapies and improved overall survival (OS) rates, most patients will experience a relapse and require additional treatments. This seminar will address health inequities and highlight the challenges and best practices associated with successful community-based approaches to patient care.
Learning Objectives:
- Describe the mechanism-of-action of new and emerging therapies for the treatment of relapsed remitting multiple myeloma (RRMM)
- Review clinical evidence on the utility and potential sequencing of new and emerging RRMM treatment approaches with or without planned transplant
- Evaluate disparities in RRMM care and overall survival rates relative to treatment setting and ethnicity, particularly black patients
- Leverage RRMM treatment advances to overcome treatment disparities and optimize patient outcomes
Target Audience:
This activity is intended for oncology nurse practitioners, physician assistants, nurses, and other healthcare providers involved in the care of cancer patients.
This Evenings in Oncology virtual program is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc.
Presented By
This Evenings in Oncology virtual program is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc.
Agenda
All Times Listed are for the Eastern Standard Time Zone
Thursday, September 12, 2024 | |
| 5:55pm | Welcome and Introduction » Carrie Bellerieve, RN (Moderator) |
| 6:00pm | Examining and Addressing Disparities in Multiple Myeloma Treatment & Outcomes » Joseph Mikhael, MD, MEd, FRCPC, FACP - Professor, Applied Cancer Research - City of Hope Cancer Center » Beth Faiman PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO - Department of Hematology and Medical Oncology - Clevland Clinic |
| 7:00pm | Closing Comments » Carrie Bellerieve, RN (Moderator) |
Faculty
Joseph Mikhael, MD, MEd, FRCPC, FACP
Dr Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF) and Director of Myeloma research at the HonorHealth Research Institute. Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis, and Waldenstrom’s macroglobulinemia. He is the PI of many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations. Dr. Mikhael also serves as the Treasurer on the executive of the American Society of Hematology.
Dr Mikhael has published over 200 peer-reviewed articles in these fields and lectures internationally on a regular basis. Dr. Mikhael is deeply committed to health disparities in myeloma and leads the diversity efforts of the IMF, namely the M-Power project in the African American community. He is also the chair of the Diversity, Equity and Inclusion Council at TGen. Dr. Mikhael is heavily involved in training future researchers and mentors junior faculty worldwide. He also spends nearly 20% of his time in the third world developing collaborations in myeloma and finding ways to enhance access to novel agents.
Beth Faiman, PhD, RN, MSN, APN-BC, BMTCN, AOCN, BMTCN, FAAN, FAPO
Beth Faiman has become an exemplary leader in bringing critical knowledge of cancer nursing to clinical providers- locally, nationally, and internationally. She demonstrates enthusiasm for continuous learning by conducting innovative research and has demonstrated the importance of using and integrating new medical knowledge within nursing practices. Dr. Faiman received her Bachelor of Science in Nursing degree from Ursuline Academy (1996), a Master of Science in Nursing at Kent State University (2002), and a PhD in clinical research from Case Western Reserve University (2014).
Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic in Ohio, and a clinical member of the Case Comprehensive Cancer Center. Faiman has over 200 peer-reviewed publications and served as an investigator on over 75 clinical trials. She has edited several books and authored many chapters and papers, including Editor of the 3rd Edition of the Multiple Myeloma Textbook for Nurses (2021), and both Editions of the Blood and Marrow Certification Manual for Nurses (2017, 2023), by ONS publishing. She previously held appointments on the American Board of Internal Medicine Maintenance of Hematology Certification Committee and American Society of Hematology.
In 2023, Faiman was given the NP/PA Educator of Distinction Award in Multiple Myeloma and in 2022, Faiman was named the Top NP in Hematology/Oncology and inducted as an inaugural Fellow of Advanced Practice in Oncology (FAPO) awarded by the Advanced Practitioner Society for Hematology and Oncology. Faiman is a Distinguished Fellow in the American Academy of Nursing (FAAN) and current Editor-in-Chief of Journal of the Advanced Practitioner in Oncology. She remains an active author, presenter, and educator on the topics of plasma cell disorders, hematology, oncology and supportive cancer care.
Disclosures:
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Available Credit
- 1.00 AMA PRA Category 1 Credit™Horizon CME designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
Price
Required Hardware/software
Access to the internet is required. Built for laptop and computer screens
Supported Browsers:
Google Chrome: Most recent stable release for Windows, Mac OS, or Linux
Microsoft Edge: Most recent stable release for Windows
Supported Phones & Tablets:
While our platform is accessible from mobile devices (ios and android) the platform is not optimized for use on devices with small screens.
Participation on a laptop or computer web browser is highly recommended.